Sevabertinib, targeting HER2 and EGFR mutations, received FDA breakthrough designation for HER2+ NSCLC, showing a 59% overall ...
The PAAG regimen significantly improved PFS and response rates in metastatic pancreatic cancer compared to chemotherapy alone ...
A Type B meeting between the FDA and Plus Therapeutics offered clarity and direction for the next steps in development of ...
Reversing the standard approved dose levels of nivolumab (Opdivo) and ipilimumab (Yervoy) in metastatic melanoma led to less ...
The FDA designates ARB1002 as an orphan drug, highlighting its potential as a novel treatment for pancreatic cancer amid ...
A blood-based colorectal cancer (CRC) screening test, SimpleScreen™, has shown a significant leap in performance, ...
Jason S. Starr, DO, assistant professor of medicine and a hematologist/oncologist in the Department of Internal Medicine at ...
ETX-19477 is a potent, selective inhibitor of poly (ADP-ribose) glycohydrolase (PARG), an enzyme that plays a role in the DNA ...
The FDA and European Medicines Agency (EMA) have awarded orphan drug designation to CPI-008 (cRGD-ZW800-1), a novel ...
Researchers explore the impact of virtual collaborative care on mental health and quality of life for breast cancer patients, ...
Z-endoxifen has demonstrated efficacy in phase 1 and 2 trials, improving progression-free survival and tumor response in ...
The phase 3 KANDLELIT-007 trial (NCT07190248) evaluating the KRAS G12C inhibitor calderasib (MK-1084) plus subcutaneous pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex; SC pembrolizumab) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback